Hikma Pharmaceuticals PLC (LSE:HIK) has announced changes at senior management level, with long-serving Chief Executive Riad Mishlawi stepping down from the role. Executive Chairman Said Darwazah will take on CEO responsibilities on an interim basis while the company begins a formal search for a permanent successor.
As part of the leadership update, Chief Financial Officer Khalid Nabilsi has been appointed to the Board, a move intended to strengthen strategic oversight and continuity. The Board said it remains confident in Hikma’s growth prospects under Said Darwazah’s leadership during the transition period.
The company confirmed that its financial guidance for 2025 is unchanged. Hikma expects to publish its full-year results in February 2026, providing further insight into operational performance and market conditions.
Despite some technical indicators pointing to near-term share price pressure, management highlighted the group’s strong financial foundations and strategic progress. Ongoing execution, combined with leadership stability, is seen as supporting longer-term growth potential.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a UK-headquartered global pharmaceutical company specialising in the development and manufacture of branded and non-branded generic medicines. With more than 45 years of operating history, the group has a strong presence across North America, the Middle East and North Africa, and Europe. Hikma is also an active licensing partner and invests in innovative healthcare technologies through its venture capital arm.
Leave a Reply